◀ Back to MMP3
MMP3 — PRG4
Text-mined interactions from Literome
Homandberg et al., Frontiers in bioscience : a journal and virtual library 1999
(Arthritis, Rheumatoid...) :
The Fn-fs up-regulate
matrix metalloproteinase ( MMP ) expression, significantly
enhance degradation and loss of
proteoglycan ( PG ) from cartilage and temporarily suppress PG synthesis, all events observed in OA
Sabatini et al., Osteoarthritis Cartilage 2002
:
This study shows that PPARgamma agonists inhibit cytokine induced
proteoglycan degradation
mediated by both aggrecanase and
MMP
Boyan et al., Connect Tissue Res 2003
:
MMP-3 is also
involved in
proteoglycan degradation, facilitating calcification
Wako et al., Spine (Phila Pa 1976) 2008
:
Introduction of TWEAK resulted in the degradation of disc matrix in organ disc culture, whereas
proteoglycan degradation was markedly abrogated in the
presence of an
MMP-3 specific inhibitor or a JNK inhibitor
Leong et al., Matrix Biol 2010
:
Intra-articular injections of an MMP-3 inhibitor, N-isobutyl-N- ( 4-methoxyphenylsulfonyl ) -glycylhydroxamic acid ( NNGH ), dampened the catabolic effects of a 7day immobilization period, indicating a likely
requirement for
MMP-3 in the regulation of
proteoglycan levels through ADAMTS-5
Homandberg et al., Biochem J 1997
:
Whereas a 1 nM concentration of an N-terminal 29 kDa fibronectin fragment ( Fn-f ) increases the
proteoglycan ( PG ) content of cartilage without induction of matrix metalloproteinases ( MMPs ), 0.1-1 microM Fn-f temporarily suppresses PG synthesis and
enhances MMP release